Literature DB >> 33895727

Association of Pre-ESRD Serum Bicarbonate with Post-ESRD Mortality in Patients with Incident ESRD.

Ekamol Tantisattamo1, Victoria Murray2, Yoshitsugu Obi1,3, Christina Park1, Christina J Catabay1, Yuji Lee1, Cachet Wenziger1, Jui-Ting Hsiung1, Melissa Soohoo1,2, Carola-Ellen Kleine1, Connie M Rhee1, Jeffrey Kraut2, Csaba P Kovesdy3,4, Kamyar Kalantar-Zadeh1, Elani Streja1.   

Abstract

BACKGROUND: Serum bicarbonate or total carbon dioxide (CO2) concentrations decline as chronic kidney disease (CKD) progresses and rise after dialysis initiation. While metabolic acidosis accelerates the progression of CKD and is associated with higher mortality among patients with end stage renal disease (ESRD), there are scarce data on the association of CO2 concentrations before ESRD transition with post-ESRD mortality.
METHODS: A historical cohort from the Transition of Care in CKD (TC-CKD) study includes 85,505 veterans who transitioned to ESRD from October 1, 2007, through March 31, 2014. After 1,958 patients without follow-up data, 3 patients with missing date of birth, and 50,889 patients without CO2 6 months prior to ESRD transition were excluded, the study population includes 32,655 patients. Associations between CO2 concentrations averaged over the last 6 months and its rate of decline during the 12 months prior to ESRD transition and post-ESRD all-cause, cardiovascular (CV), and non-CV mortality were examined by using hierarchical adjustment with Cox regression models.
RESULTS: The cohort was on average 68 ± 11 years old and included 29% Black veterans. Baseline concentrations of CO2 were 23 ± 4 mEq/L, and median (interquartile range) change in CO2 were -1.8 [-3.4, -0.2] mEq/L/year. High (≥28 mEq/L) and low (<18 mEq/L) CO2 concentrations showed higher adjusted mortality risk while there was no clear trend in the middle range. Consistent associations were observed irrespective of sodium bicarbonate use. There was also a U-shaped association between the change in CO2 and all-cause, CV, and non-CV mortality with the lowest risk approximately at -2.0 and 0.0 mEq/L/year among sodium bicarbonate nonusers and users, respectively, and the highest mortality was among patients with decline in CO2 >4 mEq/L/year.
CONCLUSION: Both high and low pre-ESRD CO2 levels (≥28 and <18 mEq/L) during 6 months prior to dialysis transition and rate of CO2 decline >4 mEq/L/year during 1 year before dialysis initiation were associated with greater post-ESRD all-cause, CV, and non-CV mortality. Further studies are needed to determine the optimal management of CO2 in patients with advanced CKD stages transitioning to ESRD.
© 2021 S. Karger AG, Basel.

Entities:  

Keywords:  Bicarbonate; Chronic kidney disease; End-stage renal disease; End-stage renal disease transition; Metabolic acidosis; Metabolic alkalosis; Mortality

Mesh:

Substances:

Year:  2021        PMID: 33895727      PMCID: PMC8184571          DOI: 10.1159/000513855

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  57 in total

1.  Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone.

Authors:  Nancy S Krieger; Christopher D Culbertson; Kelly Kyker-Snowman; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-30

Review 2.  Clinical epidemiology of cardiovascular disease in chronic renal disease.

Authors:  R N Foley; P S Parfrey; M J Sarnak
Journal:  Am J Kidney Dis       Date:  1998-11       Impact factor: 8.860

3.  Association of Pre-End-Stage Renal Disease Hemoglobin with Early Dialysis Outcomes.

Authors:  Carola-Ellen Kleine; Melissa Soohoo; Omesh N Ranasinghe; Christina Park; Maria V Marroquin; Yoshitsugu Obi; Connie M Rhee; Hamid Moradi; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; Elani Streja
Journal:  Am J Nephrol       Date:  2018-05-18       Impact factor: 3.754

4.  The clinical significance of medial arterial calcification in end-stage renal disease in women.

Authors:  Nada Abou-Hassan; Ekamol Tantisattamo; Ellen T D'Orsi; W Charles O'Neill
Journal:  Kidney Int       Date:  2014-05-28       Impact factor: 10.612

5.  Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Jürgen Bommer; Francesco Locatelli; Sudtida Satayathum; Marcia L Keen; David A Goodkin; Akira Saito; Takashi Akiba; Friedrich K Port; Eric W Young
Journal:  Am J Kidney Dis       Date:  2004-10       Impact factor: 8.860

6.  Bicarbonate supplementation slows progression of CKD and improves nutritional status.

Authors:  Ione de Brito-Ashurst; Mira Varagunam; Martin J Raftery; Muhammad M Yaqoob
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

7.  Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients.

Authors:  Kosaku Nitta; Takashi Akiba; Keiko Uchida; Shigeru Otsubo; Yuriko Otsubo; Takashi Takei; Tetsuya Ogawa; Wako Yumura; Takashi Kabaya; Hiroshi Nihei
Journal:  Hypertens Res       Date:  2004-01       Impact factor: 3.872

8.  Survival advantage in black versus white men with CKD: effect of estimated GFR and case mix.

Authors:  Csaba P Kovesdy; L Darryl Quarles; Evan H Lott; Jun Ling Lu; Jennie Z Ma; Miklos Z Molnar; Kamyar Kalantar-Zadeh
Journal:  Am J Kidney Dis       Date:  2013-01-29       Impact factor: 8.860

Review 9.  Is an increased serum bicarbonate concentration during hemodialysis associated with an increased risk of death?

Authors:  Joline L T Chen; Kamyar Kalantar-Zadeh
Journal:  Semin Dial       Date:  2014-03-13       Impact factor: 3.455

10.  Erythropoietin Dose and Mortality in Hemodialysis Patients: Marginal Structural Model to Examine Causality.

Authors:  Elani Streja; Jongha Park; Ting-Yan Chan; Janet Lee; Melissa Soohoo; Connie M Rhee; Onyebuchi A Arah; Kamyar Kalantar-Zadeh
Journal:  Int J Nephrol       Date:  2016-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.